This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
The effectiveness evidence was derived from a single study.
Methods of combining primary studies
Not applicable, given that only one study was used to derive the effectiveness data.
Investigation of differences between primary studies
Not applicable.
Results of the review
In the phenytoin group, the only adverse event was vein burning (9.1%). In the fosphenytoin group, the adverse events were hypotension (0.5%), infiltration (0.5%), burning legs and buttocks (2.5%), pruritus (7.4%), tongue swelling (0.5%) and vein burning (0.5%).
Measure of benefits used in the economic analysis
The two drug treatments were considered equally effective, therefore a cost-minimisation analysis was undertaken. The authors used the frequency of the adverse events to calculate the costs for treating the same adverse events.
Direct costs
Discounting was not carried out given the short duration of the treatment. The unit costs and resource quantities were reported separately. The boundary adopted was that of the hospital. The costs and the quantities were estimated from actual data. The total costs of the treatments were derived through the decision model. The costs of the treatment with the two drugs included medical accessories, wholesale prices from the drugs, and personnel costs. The costs of the medical accessories were derived from cost data from a purchasing organisation encompassing over 1,000 hospitals. The wholesale prices for the drugs were gathered from the 1999 Drug Topics Red Book. The personnel costs were obtained from institutional salary data. The costs of treating adverse effects were also considered and included. The resource use data were gathered in 1998. The price year was 1999. The costs and resources related to administering the drug were omitted because they were common to both treatments.
